Приказ основних података о документу

dc.creatorNovković, Mirjana
dc.creatorMatić, Dragan
dc.creatorKušić-Tišma, Jelena
dc.creatorAntonijević, Nebojša
dc.creatorRadojković, Dragica
dc.creatorRakićević, Ljiljana
dc.date.accessioned2022-11-15T15:02:11Z
dc.date.available2022-11-15T15:02:11Z
dc.date.issued2018
dc.identifier.issn0031-6970
dc.identifier.urihttps://imagine.imgge.bg.ac.rs/handle/123456789/1187
dc.description.abstractBleeding is one of the possible adverse events during clopidogrel therapy. The CYP2C19 gene is the most significant genetic factor which influences response to clopidogrel treatment. We aimed to examine the contribution of the CYP2C19 gene to bleeding occurrence during clopidogrel therapy in Serbian patients with ST segment elevation myocardial infarction (STEMI) undergoing primary percutaneous coronary intervention (PCI). This case-control study included 53 patients who experienced bleeding and 55 patients without bleeding. Bleeding events were defined and classified using the Bleeding Academic Research Consortium (BARC) criteria. All patients were prescribed daily doses of clopidogrel during the 1-year follow-up after PCI. The CYP2C19*17 (c.-806C gt T, rs12248560), rs11568732 (c.-889T gt G, CYP2C19*20), CYP2C19*2 (c.681G gt A; rs4244285) and CYP2C19*3 (c.636G gt A; rs4986893) variants were analysed in all 108 patients. Additionally, sequencing of all nine exons, 5'UTR and 3'UTR in the rs11568732 carriers was performed. Association between bleeding (BARC type ae lt yen gt 2) and the CYP2C19*17 variant was not observed [odds ratio (OR), 0.53; 95% confidence interval (CI), 0.2-1.1; p = 0.107). The rs11568732 variant showed significant association with bleeding (OR, 3.7; 95% CI, 1.12-12.44; p = 0.025). Also, we found that the rs11568732 variant appears independently of haplotype CYP2C19*3B, which is contrary to the previous findings. Our results indicate the absence of CYP2C19*17 influence and turn the attention to the potential significance of the rs11568732 variant in terms of adverse effects of clopidogrel. However, it is necessary to conduct an independent conformation study in order to verify this finding. Also, an analysis of the functional implication of the rs11568732 variant is necessary in order to confirm the significance of this variant, both in relation to its influence on gene expression and in relation to its medical significance.en
dc.publisherSpringer Heidelberg, Heidelberg
dc.relationinfo:eu-repo/grantAgreement/MESTD/Basic Research (BR or ON)/173008/RS//
dc.rightsrestrictedAccess
dc.sourceEuropean Journal of Clinical Pharmacology
dc.subjectPharmacogeneticsen
dc.subjectPCIen
dc.subjectCYP2C19en
dc.subjectClopidogrelen
dc.subjectBleedingen
dc.titleAnalysis of the CYP2C19 genotype associated with bleeding in Serbian STEMI patients who have undergone primary PCI and treatment with clopidogrelen
dc.typearticle
dc.rights.licenseARR
dc.citation.epage451
dc.citation.issue4
dc.citation.other74(4): 443-451
dc.citation.rankM22
dc.citation.spage443
dc.citation.volume74
dc.identifier.doi10.1007/s00228-017-2401-5
dc.identifier.pmid29260275
dc.identifier.scopus2-s2.0-85038396710
dc.identifier.wos000427468600006
dc.type.versionpublishedVersion


Документи

Thumbnail

Овај документ се појављује у следећим колекцијама

Приказ основних података о документу